



## KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 04, 2024

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Dec. 4, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 36,000 shares of KalVista common stock on December 2, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of \$10.27 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Inducement Equity Incentive Plan and a stock option agreement covering the grant.

### About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a global pharmaceutical company whose mission is to develop and deliver life-changing oral medicines for people affected by rare diseases with significant unmet needs. Sebetralstat, our novel, investigational candidate for the oral, on-demand treatment of hereditary angioedema, is under regulatory review by the FDA with a PDUFA goal date of June 17, 2025. In addition, we have completed Marketing Authorization Application (MAA) submissions for sebetralstat to the European Medicines Agency and the United Kingdom, Switzerland, Australia, and Singapore.

For more information about KalVista, please visit [www.kalvista.com](http://www.kalvista.com) or follow on social media at [@KalVista](https://twitter.com/KalVista) and [LinkedIn](https://www.linkedin.com/company/kalvista).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20241204815613/en/): <https://www.businesswire.com/news/home/20241204815613/en/>

### KalVista Pharmaceuticals, Inc.

#### Media:

Jenn Snyder  
Vice President, Corporate Affairs  
(857) 356-0479  
[jennifer.snyder@kalvista.com](mailto:jennifer.snyder@kalvista.com)

#### Investors:

Ryan Baker  
Head, Investor Relations  
(617) 771-5001  
[ryan.baker@kalvista.com](mailto:ryan.baker@kalvista.com)

Source: KalVista Pharmaceuticals, Inc.